PGHH Holds 62nd AGM: Approves Dividends, Reappoints Director, Appoints New Whole-time Director
PGHH held its 62nd AGM on September 8, 2026. The meeting approved financial statements, dividends, reappointed Pramod Agarwal, and appointed Srividya Srinivasan as Whole-time Director. FY26 saw flat sales and 19% PAT growth.
The AGM involved key corporate actions such as dividend declaration and director appointments, which are material for shareholders. The financial performance updates also provide important context.
The announcement details the proceedings of an Annual General Meeting, including standard business items like financial statement adoption, dividend declaration, and director appointments. While the financial highlights show positive PAT growth, the overall tone is routine and informational.
Procter & Gamble Hygiene and Health Care Limited (PGHH) held its 62nd Annual General Meeting (AGM) on September 8, 2026, conducted virtually via Video Conferencing/Other Audio Visual Means. The meeting commenced at 11:00 a.m. with the requisite quorum present. Ms. Flavia Machado, Sr. Manager- Secretarial, welcomed the shareholders, and Mr. Chittranjan Dua, Chairperson of the Board, chaired the proceedings. The Notice of AGM and Annual Report for the financial year 2025-26 were circulated electronically.
The agenda included adopting the Financial Statements for the Financial Year ended March 31, 2026, confirming interim dividend and declaring final dividend for the same period, re-appointing Mr. Pramod Agarwal as a Non-Executive Director, appointing Ms. Srividya Srinivasan as a Whole-time Director, ratifying the Cost Auditor's remuneration for 2026-27, and approving a Material Related Party Transaction for the purchase of goods.
Mr. Kumar Venkatasubramanian, Managing Director, presented the company's financial performance and business strategy. Shareholders engaged in a Q&A session with the management. The meeting concluded at 1:06 p.m. The results of the voting will be announced within two working days of the meeting's conclusion, following the Scrutinizer's Report, and will be available on the company's website. The e-voting portal closed at 1:36 p.m. The presentation highlighted flat sales and a 19% increase in PAT for FY 2025-26, with CAGR of 8% for Net Sales and 3x increase in ROE over the past 10 years.
What to do with a filing like this
Procter & Gamble Hygiene and Health Care Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Hygiene and Health Care Limited. Read the original for the full detail.